PALATIN TECHNOLOGIES INC (PTN) Stock Price, Quote, News and Overview
NYSEARCA:PTN - NYSE Arca - US6960775020 - Common Stock - Currency: USD
PTN Quote, Performance and Key Statistics
1
-0.02 (-1.96%)
The current stock price of PTN is 1 USD. In the past month the price increased by 5.26%. In the past year, price decreased by -68.05%.
PTN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About PTN
Company Profile
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. The company is headquartered in Cranbury, New Jersey and currently employs 30 full-time employees. The firm is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus primarily on MC1r agonists, with the potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. The company is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. Its product candidates include PL9643 for dry eye disease and PL8177 for the treatment of ulcerative colitis.
Company Info
PALATIN TECHNOLOGIES INC
4B Cedar Brook Drive
Cranbury NEW JERSEY 08512 US
CEO: Carl Spana
Employees: 30
Company Website: https://www.palatin.com/
Investor Relations: http://www.palatin.com/investors/overview/
Phone: 16094952200
PALATIN TECHNOLOGIES INC / PTN FAQ
What is the stock price of PALATIN TECHNOLOGIES INC today?
The current stock price of PTN is 1 USD. The price decreased by -1.96% in the last trading session.
What is the ticker symbol for PALATIN TECHNOLOGIES INC stock?
The exchange symbol of PALATIN TECHNOLOGIES INC is PTN and it is listed on the NYSE Arca exchange.
On which exchange is PTN stock listed?
PTN stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for PALATIN TECHNOLOGIES INC stock?
5 analysts have analysed PTN and the average price target is 7.14 USD. This implies a price increase of 614% is expected in the next year compared to the current price of 1. Check the PALATIN TECHNOLOGIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PALATIN TECHNOLOGIES INC worth?
PALATIN TECHNOLOGIES INC (PTN) has a market capitalization of 26.01M USD. This makes PTN a Nano Cap stock.
How many employees does PALATIN TECHNOLOGIES INC have?
PALATIN TECHNOLOGIES INC (PTN) currently has 30 employees.
What are the support and resistance levels for PALATIN TECHNOLOGIES INC (PTN) stock?
PALATIN TECHNOLOGIES INC (PTN) has a support level at 0.91 and a resistance level at 1. Check the full technical report for a detailed analysis of PTN support and resistance levels.
Is PALATIN TECHNOLOGIES INC (PTN) expected to grow?
The Revenue of PALATIN TECHNOLOGIES INC (PTN) is expected to decline by -100% in the next year. Check the estimates tab for more information on the PTN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PALATIN TECHNOLOGIES INC (PTN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PTN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PTN, evaluating the profitability, health, valuation and growth aspects
- PALATIN TECHNOLOGIES INC (PTN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PALATIN TECHNOLOGIES INC (PTN) Sales and EPS estimates to see what analysts future expectations are.
- PALATIN TECHNOLOGIES INC (PTN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PALATIN TECHNOLOGIES INC (PTN) Insider and Institutional Ownership to learn about the owners and their transactions.
- PALATIN TECHNOLOGIES INC (PTN) Stock Chart to make your own analysis
- PALATIN TECHNOLOGIES INC (PTN) Latest news and press-releases to stay up to date.
Does PALATIN TECHNOLOGIES INC (PTN) stock pay dividends?
PTN does not pay a dividend.
When does PALATIN TECHNOLOGIES INC (PTN) report earnings?
PALATIN TECHNOLOGIES INC (PTN) will report earnings on 2025-05-13, before the market open.
What is the Price/Earnings (PE) ratio of PALATIN TECHNOLOGIES INC (PTN)?
PALATIN TECHNOLOGIES INC (PTN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.54).
What is the Short Interest ratio of PALATIN TECHNOLOGIES INC (PTN) stock?
The outstanding short interest for PALATIN TECHNOLOGIES INC (PTN) is 4.35% of its float. Check the ownership tab for more information on the PTN short interest.
PTN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PTN. When comparing the yearly performance of all stocks, PTN is a bad performer in the overall market: 91.08% of all stocks are doing better.
PTN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PTN. PTN may be in some trouble as it scores bad on both profitability and health.
PTN Financial Highlights
Over the last trailing twelve months PTN reported a non-GAAP Earnings per Share(EPS) of -1.54. The EPS increased by 40.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -947.33% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PTN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to PTN. The Buy consensus is the average rating of analysts ratings from 5 analysts.
For the next year, analysts expect an EPS growth of 51.7% and a revenue growth -100% for PTN